Butyl Alcohol

Butyl Alcohol

SCHEMBL793489

CCCCO.O=C(O)O.O=C(O)O

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Butyl Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.73
SMN1; SMN2 Q16637 1/20 0.59
TSHR P16473 5/20 0.56
LMNA P02545 2/20 0.56
HSD17B10 Q99714 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
AKR1B1 P15121 1/20 0.48
GPR84 Q9NQS5 7/20 0.46
PPARG P37231 7/20 0.46
PPARD Q03181 7/20 0.46
PPARA Q07869 7/20 0.46
HDAC11 Q96DB2 5/20 0.46
PTPN1 P18031 3/20 0.46
TLR2 O60603 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
FABP4 P15090 2/20 0.46
SLC22A6 Q4U2R8 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
ESR1 P03372 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyl Alcohol SCHEMBL30712613 1.00 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10
Butyl Alcohol SCHEMBL27387947 1.00
Butyl Alcohol SCHEMBL27822054 0.97 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10
Butyl Alcohol SCHEMBL28022543 0.97 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10
Butyl Alcohol SCHEMBL27823537 0.97 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10
Butyl Alcohol SCHEMBL28157153 0.94 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10
1-Pentanol SCHEMBL6569557 0.90 SMN1; SMN2 (0.75) ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10
Butyl Alcohol SCHEMBL430466 0.90
Butyl Alcohol SCHEMBL9847540 0.90 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10
Butyl Alcohol SCHEMBL28111680 0.90 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008039007-A1 INDOL DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC DISORDER CONTAINING THE SAME AS AN ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2008-04-03 WO claimed
EP-2731710-B1 METHOD FOR PRODUCING COMPOSITES OUT OF ALUMINIUM OXIDE AND CERIUM/ZIRCONIUM MIXED OXIDES SASOL GERMANY GMBH (DE) 2019-09-04 EP disclosed
EP-3505241-A1 METHOD FOR PRODUCING COMPOSITES OUT OF ALUMINIUM OXIDE AND CERIUM/ZIRCONIUM MIXED OXIDES SASOL Germany GmbH (DE) 2019-07-03 EP disclosed
EP-2545990-B1 Method for producing composites out of aluminium oxide and cerium/zirconium mixed oxides SASOL GERMANY GMBH (DE) 2018-11-28 EP disclosed
EP-2731710-A1 METHOD FOR PRODUCING COMPOSITES FROM ALUMINIUM OXIDE AND CERIUM/ZIRCONIUM MIXED OXIDES SASOL Germany GmbH (DE) 2014-05-21 EP disclosed
EP-2616072-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2013-07-24 EP disclosed
WO-2013007242-A1 METHOD FOR PRODUCING COMPOSITES FROM ALUMINIUM OXIDE AND CERIUM/ZIRCONIUM MIXED OXIDES SASOL GERMANY GMBH (DE) 2013-01-17 WO disclosed
EP-2545990-A1 Method for producing composites out of aluminium oxide and cerium/zirconium mixed oxides SASOL Germany GmbH (DE) 2013-01-16 EP disclosed
WO-2012035039-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-03-22 WO disclosed
WO-2011095997-A1 BENZAMIDE COMPOUNDS AS GLUCOKINASE ACTIVATORS AND THEIR PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2011-08-11 WO disclosed
EP-1385508-A1 DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES Merck & Co., Inc. (US) 2004-02-04 EP disclosed
EP-1295123-A1 SELECTIVE LABELING AND ISOLATION OF PHOSPHOPEPTIDES AND APPLICATIONS TO PROTEOME ANALYSIS UNIVERSITY OF WASHINGTON (US) 2003-03-26 EP disclosed
EP-1200432-A4 AMIDO SPIROPIPERIDINES PROMOTE THE RELEASE OF GROWTH HORMONE MERCK & CO INC (US) 2003-01-29 EP disclosed
WO-2002076450-A1 DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2002-10-03 WO disclosed
EP-1200432-A1 AMIDO SPIROPIPERIDINES PROMOTE THE RELEASE OF GROWTH HORMONE Merck & Co., Inc. (US) 2002-05-02 EP disclosed
WO-2001096869-A1 SELECTIVE LABELING AND ISOLATION OF PHOSPHOPEPTIDES AND APPLICATIONS TO PROTEOME ANALYSIS UNIVERSITY OF WASHINGTON (US) 2001-12-20 WO disclosed
WO-2001004119-A1 AMIDO SPIROPIPERIDINES PROMOTE THE RELEASE OF GROWTH HORMONE MERCK & CO., INC. (US) 2001-01-18 WO disclosed
EP-0699079-A1 BIOACTIVE AND/OR TARGETED DENDRIMER CONJUGATES THE DOW CHEMICAL COMPANY (US) 1996-03-06 EP disclosed
EP-0687675-A2 Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof LG Chemical Limited (KR) 1995-12-20 EP disclosed
WO-1995024221-A1 BIOACTIVE AND/OR TARGETED DENDRIMER CONJUGATES THE DOW CHEMICAL COMPANY (US) 1995-09-14 WO disclosed